HEB

[setravis]

HEB...Poised to Plunge ? 

How can they do it? Just look at the last month. Dilutive financings of 16M and 18M completed with lightning speed as the share price rose prior to the 5/25 PDUFA. Think these guys have any confidence that they'll get approval? Obviously not or they'd wait until their share price was at 10 after approval to raise cash.
That 34M will keep them paid for another three years, plenty of time to make BS excuses for Ampligen rejection and invent new diseases to cure with it.

Between Swine Flu and the success of Dendreon, most biopharmaceutical's are taking some rides of late. Good, bad, and plain ugly, they rise and fall in leaps and bounds. Hemispherx BioPharma could get me "in trouble". This is it's second huge ride up in the last week. It really looked like it was heading up and out of sight until a new equity offering was priced at $1.34 just after the stock had soared in two days from $0.90 to $2.00. The equity pricing dropped the stock like a rock the next day back to $1.40, or near the diluting issue price.

"When people saw a penny stock like Vanda could move up 1000%, that created excitement for the next one. Traders are looking for the next Vanda, or at least they're hyping some of these stocks in the hope that someone believes they're the next Vanda."

[setravis]

she still moves up...

[setravis]

Back from the grave...

But the 239 companies in the biotech sector enjoyed returns of better than 34% over the past 30 days. Vanda's up more than 1,000%, Hemispherix has more than quintupled, and you'll find a number of other biotech names populating the list of top-performing stocks these days.

That good news stems from a variety of reasons. Vanda shook the market when its schizophrenia drug Fanapt got FDA approval, and Novavax got a lift from the swine flu outbreak. Meanwhile, Hemispherix is still waiting for FDA approval of its chronic fatigue syndrome treatment Ampligen, but that hasn't stopped speculators from bidding up the shares anyway...


52wk Range: 0.25 - 3.98
Volume: 38,340,843
Avg Vol (3m): 4,834,680

Technicals
Record Volume
Record Price High
Most Actives
Percentage Gainer

Last Price Quote is:
86.64%above 13-day MA
217.98%above 50-day MA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $72.69 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Market Perform

[setravis]

A 'Pandemic' Now Declared, Focus Back on Swine Flu Stocks
On Friday June 12, 2009, 12:00 pm EDT

The H1N1 virus is officially a pandemic, and vaccine stocks are responding.

Swine flu stocks are up again today, with some extending weekly gains to more than 20%. A number of companies released good news to end the week. From small-cap players to multi-billion dollar giants, shares are up big on high volume. Novartis (NYSE: NVS) announced today that it will have a swine flu vaccine ready by this fall. Shares are up by 4% on the news.

On Thursday, the World Health Organization raised its alert level on the virus to "Phase 6," indicating that it has officially become a pandemic.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 2.5%. It is now beating the S&P 500 by 35.5% over the last month.

Generex Biotechnology (NASDAQ: GNBT) is leading the Index today with 10% gains. The company was granted five new patents for its drug delivery systems. The patents were awarded in Canada, Australia, New Zealand, Brazil, and Lebanon. The stock is still in negative territory this week by -3%.

Sinovac Biotech (AMEX: SVA) is adding another 3% to its industry-leading 30% weekly rally. On Monday the company announced that it had begun production of a swine flu vaccine, and noted that it could produce up to 30 million doses per year.

Vical (NASDAQ: VICL) has fallen from earlier highs, and is now trading up fractionally. Thomas Weisel initiated coverage of the company today with an Overweight rating and a $5 price target. The analyst cited Vical's proprietary technology, strategic partnerships, and licensing agreements.

GlaxoSmithKline (NYSE: GSK) and Hemispherx Biopharma (AMEX: HEB) are both ahead by more than 4% today.

Pure Bioscience (NASDAQ: PURE) and AVI Biopharma (NASDAQ: AVII) are industry laggards today, falling by -3% and -6% respectively.

As of this writing the Swine Flu and Bird Flu Stocks Index is a top-three performing tickerspy Index over the last month, gaining 39.5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.
http://www.tickerspy.com/index/Swine-Flu-and-Bird-Flu-Stocks?refer=2028Y3
   

[setravis]

A 'Pandemic' Now Declared, Focus Back on Swine Flu Stocks
On Friday June 12, 2009, 12:00 pm EDT

The H1N1 virus is officially a pandemic, and vaccine stocks are responding.

Swine flu stocks are up again today, with some extending weekly gains to more than 20%. A number of companies released good news to end the week. From small-cap players to multi-billion dollar giants, shares are up big on high volume. Novartis (NYSE: NVS) announced today that it will have a swine flu vaccine ready by this fall. Shares are up by 4% on the news.

On Thursday, the World Health Organization raised its alert level on the virus to "Phase 6," indicating that it has officially become a pandemic.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 2.5%. It is now beating the S&P 500 by 35.5% over the last month.

Generex Biotechnology (NASDAQ: GNBT) is leading the Index today with 10% gains. The company was granted five new patents for its drug delivery systems. The patents were awarded in Canada, Australia, New Zealand, Brazil, and Lebanon. The stock is still in negative territory this week by -3%.

Sinovac Biotech (AMEX: SVA) is adding another 3% to its industry-leading 30% weekly rally. On Monday the company announced that it had begun production of a swine flu vaccine, and noted that it could produce up to 30 million doses per year.

Vical (NASDAQ: VICL) has fallen from earlier highs, and is now trading up fractionally. Thomas Weisel initiated coverage of the company today with an Overweight rating and a $5 price target. The analyst cited Vical's proprietary technology, strategic partnerships, and licensing agreements.

GlaxoSmithKline (NYSE: GSK) and Hemispherx Biopharma (AMEX: HEB) are both ahead by more than 4% today.

Pure Bioscience (NASDAQ: PURE) and AVI Biopharma (NASDAQ: AVII) are industry laggards today, falling by -3% and -6% respectively.

As of this writing the Swine Flu and Bird Flu Stocks Index is a top-three performing tickerspy Index over the last month, gaining 39.5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.
http://www.tickerspy.com/index/Swine-Flu-and-Bird-Flu-Stocks?refer=2028Y3
   

[setravis]

Some up-and-coming stocks will find their way into the Russell indexes, such as Hemispherx Biopharma (AMEX: HEB)

What it means
The most important thing about major changes to indexes is that because so many institutional investors work hard to match index returns, changes result in a flurry of trading activity during the transition period. With most indexes, though, including the S&P 500 and the Dow Industrials, changes aren't made on a regular basis. Instead, substitutions are made more on an as-needed basis, which limits the opportunity for traders to take advantage of index funds and other index-tracking investors.

The Russell reconstitution, however, is remarkable because of its regularity. Many investors rush to buy shares of newly added companies in an attempt to beat the index funds to the punch. To try to reduce the impact of the changes, Russell lengthens its process to give institutional investors more time to make trades and realign their portfolios to match up with the new lists.

Can you profit from the changes?
Nevertheless, the predictability of the changes imposes a cost on those who follow the index's changes strictly. Past research has concluded that the forced behavior that index changes impose on the funds that follow them costs investors an average of 2 percentage points every year.

A more recent look at this year's stocks suggests that those conclusions continue to be true. According to a Goldman Sachs study, stocks expected to be added this year have outperformed the overall index by 3.4 percentage points between April 1 and May 4. Stocks to be removed, on the other hand, have underperformed by 6.5 percentage points over the same period.

Nevertheless, some index-trackers prefer not to deal with Russell's annual process. Although the iShares Russell 2000 (IWM) tracks Russell's small-cap index, the Vanguard Small-Cap ETF (VB) chooses to follow a different index, the MSCI small-cap index. That helps the Vanguard fund avoid the June madness.

What to do
With so many hedge funds and sophisticated investors trying to take advantage of the short-term impact on stocks affected by the Russell reconstitution, you're unlikely to cash in with a swing trade. However, that doesn't mean you should ignore the process entirely.

If you own shares of companies that are slated to be removed from the index, then you might want to sell shares before the final reconstitution on June 26 in order to avoid the selling pressure resulting from the index changes. Alternatively, if you really think a stock has good long-term prospects, make sure you're prepared for a potential drop on that day -- and don't panic-sell after the fact.

Conversely, if any of the stocks on the prospective list of additions are attractive to you, you might want to buy sooner than later. If being included in the index pushes share prices higher, you'll be glad you didn't wait.

[setravis]

FDA approval + Swine flu...
FDA approval decision should come any day.

Japanese National Institute of Infectious Diseases Scientists Identify Hemispherx Biopharma's Drug Technology as the "Most Promising Mucosal Adjuvant for Influenza. Recognition for this application alone would justify a higher price. If FDA does not happen it could drop (but should stay above recent levels) before going subtantionaly higher - hence the 6 months term.

52wk Range: 0.25 - 4.54
Volume: 20,789,388
Avg Vol (3m): 8,010,090


Technicals
Close Above the 13-day MA
Most Actives
Percentage Gainer

Last Price Quote is:
21.91%above 13-day MA
61.39%above 50-day MA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $72.69 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Market Perform

Picked up good support at the 50-day MA ,and took a nice bounce!

[setravis]

Hemispherx Biopharma to Provide Update On Global Pandemic Influenza Prevention / Treatment Initiatives
Press Release
Source: Hemispherx Biopharma, Inc.
On Monday July 20, 2009, 8:00 am EDT

PHILADELPHIA, July 20, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE AMEX:HEB) will provide an update on its Influenza research initiatives via teleconference on Wednesday, July 22, 2009, at 10:00 AM EDT. Initiatives to be discussed will include experimental programs planned or underway in Pacific Rim countries, Australia, South America and the United States. Background information may be sourced at Wall Street Journal, July 18/19, 2009, p. A3.

Hemispherx's Medical Director, CEO, and the Managing Director of the Sage Group, a health care consulting firm retained by Hemispherx, will participate. Investigational products and protocols to be discussed will include Hemispherx's Ampligen(r) (poly I: poly C12U), Alferon N (a natural cocktail of alpha 2 type interferons, FDA approved for treatment of refractory HPV) and Alferon LDO, an experimental formulation of Alferon-N for oral delivery.




To access the conference call:
U.S. Callers: 800-346-7359
International Callers: 973-528-0008
Conference Entry Code: 27781

This call will be webcast via the Company's website at: http://www.hemispherx.net.




A digital replay of the call will be available until August 5, 2009
by calling:
U.S. Callers: 800-332-6854
International Callers: 973-528-0005
Conference Entry Code: 27781

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is a specialty pharma company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(r) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics, Ampligen(r) and Oragens. Ampligen(r) and Oragens represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 50 issued patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(r)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(r), Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(r) do not imply that the product will ever be specifically approved commercially for these other treatment indications; similarly, the completion of the NDA filing process with Ampligen(r) does not imply that the product will ever be approved commercially.

Contact:
Hemispherx Biopharma, Inc.Company/Investor Contact:Dianne [email protected]

[setravis]

Traders Flock to Vaccine Stocks Ahead of Conference
By the tickerspy.com Staff
On Tuesday July 21, 2009, 12:58 pm EDT

Selected vaccine stocks traded up by as much as 17% on Tuesday.

Last week we covered the renewed hype surrounding swine flu moving into the fall. Already, stocks are swinging wildly in anticipation of Thursday's meeting of the Vaccines and Related Biological Products Advisory Committee. The committee, which consists of 12 core voting members under the umbrella of the Food and Drug Administration, is to discuss the use of vaccines in relation to the 2009 outbreak of the H1N1 virus.

As a whole, the Swine and Bird Flu Stocks Index is adding 3.6% to its 14% five-day rally. The Index is currently outperforming the S&P 500 by 8% over the last month.

Today's top performer is BioCryst Pharmaceuticals (NASDAQ: BCRX - News), which is trading higher by 17%. The stock had traded flat since gapping up nearly 50% on Friday's open. The prior jump came after the company announced positive results from its Phase III flu vaccine study.

Hemispherx Biopharma (AMEX: HEB - News) is up over 40% in the last two days after announcing its plan to provide an update on its flu research. Investors will be listening carefully during the company's conference call tomorrow at 10:00 am ET.

Novavax (NASDAQ: NVAX - News) takes a distant third in the weekly performance rankings, up 13.7%.

A number of major pharmaceutical companies have operations devoted to the H1N1 virus, but diversification makes them immune to intraday swine flu speculation. GlaxoSmithKline (NYSE: GSK - News), Roche (OTC: RHHBY - News), and Sanofi-Aventis (NYSE: SNY - News) are all ahead fractionally while Novartis (NYSE: NVS - News) is adding 1% to its impressive 10% five-day rally.

As of this writing, the Swine Flu Stocks Index is one of the top-20 performing tickerspy Indexes over the last month, up 11%.

Investors can follow the Swine and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Fun and informative, tickerspy.com is a free investing website where you can track multiple stock portfolios and compare against 250 proprietary Indexes tracking themes from nanotech to agriculture to precious metals. Best of all, tickerspy.com lets you spy on the portfolios of nearly 3,000 Wall Street institutions and hedge funds and see graphs of their performance. Try tickerspy.com today and find out how you stack up against investing legends like Warren Buffett!

[setravis]

Yesterday...HGSI...Today...HEB !
Strong breakout coming...
Symmetric Triangle went tight up between 13 and 50 day. Potential big win ahead 
Chart is ready to explode lots of consolidation...


52wk Range: 0.25 - 4.54
Volume: 32,305,404
Avg Vol (3m): 9,306,860

Technicals
Close Above the 13-day MA
Most Actives
Gap Up
Percentage Gainer

Last Price Quote is:
55.27%above 13-day MA
72.47%above 50-day MA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $72.69 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Market Perform

[setravis]

Also reference here...
http://www.3stocksonfire.org/trading/index.php?topic=7100.msg119331#msg119331